Professor John Radford is a Consultant Medical Oncologist based at The Christie NHS Foundation Trust.

Professor Radford is Director of Research at the Christie, Clinical Lead for the Manchester Cancer Research Centre (MCRC) and Clinical Academic Section Lead for cancer in the Manchester Academic Health Science Centre (MAHSC).

Professor Radford is also the Teenage Cancer Trust Professor of Teenage and Young Adult Cancer at the University of Manchester and Director of Research.

His research interests are focused on developing and testing new ways of treating lymphoma and monitoring the effectiveness of these treatments using novel biomarkers.  He is also interested in studying the late effects of chemotherapy on fertility, heart function and the risk of second cancers and is investigating how best to prevent or minimise the impact of these in people cured of lymphoma. He is an advocate of patient choice in health care systems and believes that patient organisations have an important role in terms of providing information and support and influencing the development of national policy.

Professor Radford sits on the UK NCRI (National Cancer Research Institute) Lymphoma Clinical Studies Group, chairs the NCRI Hodgkin Lymphoma sub-group, is chair of the Manchester Lymphoma Group, a member of the MCRC (Manchester Cancer Research Centre) Research Strategy Group, the NCRI Survivorship cross-cutting working group, the medical panel of the Lymphoma Association (UK national patient group). He also sits on the Board of MIMIT (Manchester; Integrating Medicine and Innovative Technology) and is chief investigator for several national/international trials. He has advised the Parliamentary Ombudsman, NICE and the National Horizon Scanning Centre and is a member of the Editorial Board of the Journal of Clinical Oncology.